Pharmacogenomics in neurology: current state and future steps (Q37967607)

26 August 2017

Pharmacogenomics in neurology: current state and future steps (English)

1 reference

26 August 2017

1 reference

2

1 reference

26 August 2017

Andrew Chan

1

1 reference

PubMed ID

22162054

26 August 2017

Manuel Comabella

series ordinal

3

1 reference

26 August 2017

1 November 2011

1 reference

26 August 2017

1 reference

26 August 2017

70

1 reference

26 August 2017

5

1 reference

26 August 2017

684-697

1 reference

Pharmacological treatment of early multiple sclerosis

26 August 2017

1 reference

Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients

21 January 2018

1 reference

IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.

21 January 2018

1 reference

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

21 January 2018

1 reference

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

21 January 2018

1 reference

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

21 January 2018

1 reference

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment

21 January 2018

1 reference

Drug resistance in brain diseases and the role of drug efflux transporters.

21 January 2018

1 reference

Immunosuppression in clinical practice: approaches to individualized therapy

21 January 2018

1 reference

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

21 January 2018

1 reference

Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs

21 January 2018

1 reference

Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain

21 January 2018

1 reference

Pharmacogenetics of warfarin: current status and future challenges

21 January 2018

1 reference

Warfarin: almost 60 years old and still causing problems

21 January 2018

1 reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

21 January 2018

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping?

21 January 2018

1 reference

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

The evolving field of stroke prevention in patients with atrial fibrillation

21 January 2018

1 reference

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.

21 January 2018

1 reference

Predisposition to epilepsy--does the ABCB1 gene play a role?

21 January 2018

1 reference

Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study

21 January 2018

1 reference

Genetic factors in the predisposition to drug-induced hypersensitivity reactions

21 January 2018

1 reference

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future

21 January 2018

1 reference

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan

21 January 2018

1 reference

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

21 January 2018

1 reference

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease

21 January 2018

1 reference

The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease

21 January 2018

1 reference

Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease

21 January 2018

1 reference

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

21 January 2018

1 reference

Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients

21 January 2018

1 reference

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study

21 January 2018

1 reference

Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease

21 January 2018

1 reference

Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease.

21 January 2018

1 reference

L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism

21 January 2018

1 reference

Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease

21 January 2018

1 reference

Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks".

21 January 2018

1 reference

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.

21 January 2018

1 reference

Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD

21 January 2018

1 reference

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.

21 January 2018

1 reference

Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients

21 January 2018

1 reference

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease.

21 January 2018

1 reference

Donepezil therapy in clinical practice: a randomized crossover study

21 January 2018

1 reference

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease

21 January 2018

1 reference

Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease

21 January 2018

1 reference

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study

21 January 2018

1 reference

Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease

21 January 2018

1 reference

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine

21 January 2018

1 reference

A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease.

21 January 2018

1 reference

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease

21 January 2018

1 reference

Tacrine-induced liver damage: an analysis of 19 candidate genes

21 January 2018

1 reference

Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity.

21 January 2018

1 reference

Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis

21 January 2018

1 reference

The phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan

21 January 2018

1 reference

G protein beta3 polymorphism and triptan response in cluster headache

21 January 2018

1 reference

Association of a human G-protein beta3 subunit variant with hypertension

21 January 2018

1 reference

A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache

21 January 2018

1 reference

Platinum neurotoxicity pharmacogenetics

21 January 2018

1 reference

FDA drug approval summaries: oxaliplatin

21 January 2018

1 reference

Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy

21 January 2018

1 reference

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

21 January 2018

1 reference

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie

21 January 2018

1 reference

Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway

21 January 2018

1 reference

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia

21 January 2018

1 reference

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia

21 January 2018

1 reference

Diagnosis, natural history, and management of Charcot–Marie–Tooth disease

21 January 2018

1 reference

Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles

21 January 2018

1 reference

The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

21 January 2018

1 reference

Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1

21 January 2018

1 reference

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

21 January 2018

1 reference

The Relationship between COMT Genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's Disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.22502

1 reference

26 August 2017

1 reference

PubMed ID

22162054